MX2023004275A - Anticuerpos biespecificos anti-pd-1/cd40 y usos de los mismos. - Google Patents

Anticuerpos biespecificos anti-pd-1/cd40 y usos de los mismos.

Info

Publication number
MX2023004275A
MX2023004275A MX2023004275A MX2023004275A MX2023004275A MX 2023004275 A MX2023004275 A MX 2023004275A MX 2023004275 A MX2023004275 A MX 2023004275A MX 2023004275 A MX2023004275 A MX 2023004275A MX 2023004275 A MX2023004275 A MX 2023004275A
Authority
MX
Mexico
Prior art keywords
bispecific antibodies
antigen
binding protein
protein constructs
binding
Prior art date
Application number
MX2023004275A
Other languages
English (en)
Spanish (es)
Inventor
Yi Yang
Yuelei Shen
Baihong Liu
Original Assignee
Eucure Beijing Biopharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eucure Beijing Biopharma Co Ltd filed Critical Eucure Beijing Biopharma Co Ltd
Publication of MX2023004275A publication Critical patent/MX2023004275A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2023004275A 2020-10-14 2021-10-13 Anticuerpos biespecificos anti-pd-1/cd40 y usos de los mismos. MX2023004275A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020120918 2020-10-14
CN2021085335 2021-04-02
PCT/CN2021/123438 WO2022078357A1 (en) 2020-10-14 2021-10-13 Anti-pd-1/cd40 bispecific antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2023004275A true MX2023004275A (es) 2023-05-02

Family

ID=81207517

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004275A MX2023004275A (es) 2020-10-14 2021-10-13 Anticuerpos biespecificos anti-pd-1/cd40 y usos de los mismos.

Country Status (11)

Country Link
US (1) US20230220082A1 (https=)
EP (1) EP4229096A4 (https=)
JP (1) JP2023545521A (https=)
KR (1) KR20230092932A (https=)
CN (1) CN116390755A (https=)
AU (1) AU2021359495A1 (https=)
BR (1) BR112023006989A2 (https=)
CA (1) CA3197463A1 (https=)
IL (1) IL302042A (https=)
MX (1) MX2023004275A (https=)
WO (1) WO2022078357A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117624372A (zh) * 2022-08-26 2024-03-01 北京天广实生物技术股份有限公司 靶向cd40和pd-l1的抗体及其用途
CN116023495B (zh) * 2022-09-05 2023-10-03 上海百英生物科技股份有限公司 一种抗cd40纳米抗体及其制备方法与应用
KR20250071228A (ko) * 2022-09-20 2025-05-21 커러스 바이오로직스 피티와이 엘티디 고갈된 면역 세포를 구제하는 방법
CN120584137A (zh) * 2023-01-06 2025-09-02 阿帕特夫研究和发展有限公司 双特异性pd-l1和cd40结合分子以及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110114089A (zh) * 2016-11-02 2019-08-09 埃派斯进有限公司 组合中的抗cd40抗体及其使用方法
EP3755716A4 (en) * 2018-02-23 2021-08-04 Eucure (Beijing) Biopharma Co., Ltd ANTI-PD-1 ANTIBODIES AND USES THEREOF
EP3823987A4 (en) * 2018-07-20 2022-03-02 Eucure (Beijing) Biopharma Co., Ltd ANTI-CD40 ANTIBODIES AND USES THEREOF
JP7575100B2 (ja) * 2018-11-13 2024-10-29 ジェイエヌ バイオサイエンシーズ エルエルシー 免疫細胞活性化のための二重特異性抗体
KR20220103957A (ko) * 2019-10-23 2022-07-25 리브젠 바이오파마 홀딩스 리미티드 항-cd40 결합 분자 및 이를 포함하는 이중-특이적 항체

Also Published As

Publication number Publication date
IL302042A (en) 2023-06-01
AU2021359495A1 (en) 2023-04-13
JP2023545521A (ja) 2023-10-30
EP4229096A1 (en) 2023-08-23
CN116390755A (zh) 2023-07-04
US20230220082A1 (en) 2023-07-13
CA3197463A1 (en) 2022-04-21
BR112023006989A2 (pt) 2024-01-02
EP4229096A4 (en) 2024-06-12
WO2022078357A1 (en) 2022-04-21
KR20230092932A (ko) 2023-06-26

Similar Documents

Publication Publication Date Title
MX2023004275A (es) Anticuerpos biespecificos anti-pd-1/cd40 y usos de los mismos.
PH12021551487A1 (en) Tumor-targeted agonistic cd28 antigen binding molecules
PH12020550214A1 (en) Antibodies specific to cd47 and pd-l1
PH12021550361A1 (en) Anti-avb8 antibodies and compositions and uses thereof
PH12022551298A1 (en) Antibodies specific for cd47, pd-l1, and uses thereof
MX2023014458A (es) Anticuerpos anti-ccr8 y usos de los mismos.
WO2020039321A8 (en) Anti-gdf15 antibodies, compositions and methods of use
JOP20180042A1 (ar) نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
AU2018366199A1 (en) Bispecific and monospecific antibodies using novel anti-PD-1 sequences
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
PH12018550179A1 (en) Anti-pd-1 antibodies, method for producing same and method for using same
MY194994A (en) Heterodimeric immunoglobulin constructs and preparation methods thereof
WO2019060750A3 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
EP3812398A3 (en) Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
EP4681726A3 (en) Anti-par2 antibodies and uses thereof
EP4556020A3 (en) Antibody molecules
WO2013188693A8 (en) Antigen binding constructs to cd3
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
EA201990672A1 (ru) Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты
PH12019502298A1 (en) Monoclonal antibody to pd-l1
MX2024015072A (es) Anticuerpos anti-egfr/met y usos de los mismos
EP4541819A3 (en) Anti-cd3 epsilon antibodies
AU2019433019A8 (en) Antibodies binding CD40 and uses thereof
WO2020218951A3 (ru) Моноклональное антитело, которое специфически связывается с gitr
EP4495142A3 (en) Bispecific antigen binding construct